TD Private Client Wealth LLC Purchases 2,501 Shares of Haleon plc (NYSE:HLN)

TD Private Client Wealth LLC grew its position in Haleon plc (NYSE:HLN) by 9.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,463 shares of the company’s stock after acquiring an additional 2,501 shares during the quarter. TD Private Client Wealth LLC’s holdings in Haleon were worth $272,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of HLN. Sierra Ocean LLC bought a new position in Haleon in the fourth quarter worth $26,000. Versant Capital Management Inc boosted its position in shares of Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after acquiring an additional 3,348 shares in the last quarter. Toronto Dominion Bank increased its stake in Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after acquiring an additional 3,470 shares during the period. Geneos Wealth Management Inc. acquired a new position in Haleon in the fourth quarter worth about $35,000. Finally, Spire Wealth Management bought a new position in Haleon during the fourth quarter worth about $39,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of NYSE:HLN opened at $10.13 on Tuesday. The business has a fifty day moving average of $9.87 and a 200-day moving average of $9.88. The firm has a market cap of $45.88 billion, a PE ratio of 29.81, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a twelve month low of $7.99 and a twelve month high of $10.80.

Haleon (NYSE:HLN) last announced its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, equities research analysts predict that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. This is a boost from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is 58.97%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. HSBC reaffirmed a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Finally, Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.